Clinical significance of performing 18F-FDG PET on patients with gastrointestinal stromal tumors: A summary of a Japanese multicenter study

Annals of Nuclear Medicine

Volumn 23, Issue 5, 2009, Pages 459-464

  Kaneta, Tomohiro ^a   Takahashi, Shoki ^a   Fukuda, Hiroshi ^b   Arisaka, Yukiko ^c   Oriuchi, Noboru ^c   Hayashi, Takayuki ^d   Fujii, Hirofumi ^d   Terauchi, Takashi ^e   Tateishi, Ukihide ^f   Kubota, Kazuo ^g   Hara, Tadashi ^h   Nakamoto, Yuji ^h   Kitajima, Kazuhiro ⁱ   Murakami, Koji ⁱ  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c GUNMA UNIVERSITY   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^e NATIONAL CANCER CENTER   (Japan)

^f YOKOHAMA CITY UNIVERSITY   (Japan)

^g NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^h KYOTO UNIVERSITY   (Japan)

ⁱ DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

18F Fluorodeoxyglucose (FDG); Gastrointestinal stromal tumor (GIST); Positron emission tomography (PET)

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; JAPANESE; MALE; MULTICENTER STUDY; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; TUMOR DIAGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; JAPAN; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES;

EID: 70349561526     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12149-009-0257-1     Document Type: Article

References (31)

1. M Miettinen J Lasota 2001 Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis Virchows Arch 438 1 12 11213830 10.1007/s004280000338 1:CAS:528:DC%2BD3MXlt1Kquw%3D%3D (Pubitemid 32128184)
2. CL Corless JA Fletcher MC Heinrich 2004 Biology of gastrointestinal stromal tumors J Clin Oncol 22 3813 3825 15365079 10.1200/JCO.2004.05.140 1:CAS:528:DC%2BD2cXhtVCitb%2FL (Pubitemid 41095223)
3. Rosai J. Gastrointestinal tract. In: Rosai J, Ewing J, editors. Ackerman's surgical pathology. St Louis: Mosby Year-Book; 1996. p. 645-6932.
4. T Hasegawa Y Matsuno T Shimoda S Hirohashi 2002 Gastrointestinal stromal tumor: Consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade Hum Pathol 33 669 676 12152168 10.1053/hupa.2002.124116 (Pubitemid 34827550)
5. M Taniguchi T Nishida S Hirota K Isozaki T Ito T Nomura, et al. 1999 Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors Cancer Res 59 4297 4300 10485475 1:CAS:528:DyaK1MXlvVSms7o%3D
6. RP DeMatteo JJ Lewis D Leung SS Mudan JM Woodruff MF Brennan 2000 Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival Ann Surg 231 51 58 10636102 10.1097/00000658-200001000- 00008 1:STN:280:DC%2BD3c7gtVSmtQ%3D%3D (Pubitemid 30043939)
7. AD Van den Abbeele 2008 The lessons of GIST-PET and PET/CT: a new paradigm for imaging Oncologist 13 Suppl 2 8 13 18434632 10.1634/theoncologist. 13-S2-8
8. S Stroobants J Goeminne M Seegers S Dimitrijevic P Dupont J Nuyts, et al. 2003 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Gleevec) Eur J Cancer 39 2012 2020 12957455 10.1016/S0959-8049(03)00073-X 1:CAS:528: DC%2BD3sXmvVKgt74%3D (Pubitemid 37297757)
9. G Antoch J Kanja S Bauer H Kuehl K Renzing-Koehler J Schuette, et al. 2004 Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI-571) therapy in patients with gastrointestinal stromal tumors J Nucl Med 45 357 365 15001674 1:CAS:528:DC%2BD2cXivVCjur0%3D
10. A Van den Abbeele R Badawi J Cliche M Janicek R Tetrault T Spangler, et al. 2002 18F-FDG-PET predicts response to imatinib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors (GIST) Proc Am Soc Clin Oncol 21a 403a abstr 1610
11. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280: DC%2BD3c7it1Gitg%3D%3D
12. JS Gold RP Dematteo 2006 Combined surgical and molecular therapy: the gastrointestinal stromal tumor model Ann Surg 244 176 184 16858179 10.1097/01.sla.0000218080.94145.cf (Pubitemid 44305531)
13. CP Raut JA Morgan SW Ashley 2009 Current issues in gastrointestinal stromal tumors: incidence, molecular biology, and contemporary treatment of localized and advanced disease Curr Opin Gastroenterol 23 149 158
14. KK Richter C Schmid M Thompson-Fawcett U Settmacher A Altendorf-Hofmann 2008 Long-term follow-up in 54 surgically treated patients with gastrointestinal stromal tumours Langenbecks Arch Surg 393 949 955 18338179 10.1007/s00423-008- 0318-2
15. CD Fletcher JJ Berman C Corless F Gorstein J Lasota BJ Longley, et al. 2002 Diagnosis of gastrointestinal stromal tumors: a consensus approach Hum Pathol 33 459 465 12094370 10.1053/hupa.2002.123545 (Pubitemid 34747864)
16. M Yamada Y Niwa T Matsuura R Miyahara A Ohashi O Maeda, et al. 2007 Gastric GIST malignancy evaluated by 18FDG-PET as compared with EUS-FNA and endoscopic biopsy Scand J Gastroenterol 42 633 641 17454885 10.1080/ 00365520601040450 (Pubitemid 46633822)
17. Y Kamiyama R Aihara T Nakabayashi E Mochiki T Asao H Kuwano, et al. 2005 18F-fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors World J Surg 29 1429 1435 16222452 10.1007/s00268-005-0045-6 (Pubitemid 41712677)
18. JY Blay S Bonvalot P Casali H Choi M Debiec-Richter AP Dei Tos 2005 et al. GIST consensus meeting panelists. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO Ann Oncol 16 566 578 15781488 10.1093/annonc/mdi127 (Pubitemid 40613322)
19. EH Ng RE Pollock MM Romsdahl 1992 Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas Cancer 69 1334 1341 1540870 10.1002/1097-0142(19920315)69:6<1334::AID-CNCR2820690606>3.0.CO;2-S 1:STN:280:DyaK387nsVSmtQ%3D%3D
20. 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors J Nucl Med 45 17 21 14734662 1:CAS:528:DC%2BD2cXht1artLY%3D
21. GS Meirelles G Ravizzini HW Yeung T Akhurst 2006 Esophageal leiomyoma: a rare cause of false-positive FDG scans Clin Nucl Med 31 342 344 16714896 10.1097/01.rlu.0000218771.35887.7a (Pubitemid 44310002)
22. H Joensuu PJ Roberts M Sarlomo-Rikala LC Andersson P Tervahartiala D Tuveson, et al. 2001 Effect of the tyrosine kinase inhibitor STI-571 in a patient with a metastatic gastrointestinal stromal tumor N Engl J Med 344 1052 1056 11287975 10.1056/NEJM200104053441404 1:STN:280:DC%2BD3M3gvVekuw%3D%3D (Pubitemid 32267975)
23. K Pietras A Ostman M Sjoquist E Buchdunger RK Reed CH Heldin, et al. 2001 Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors Cancer Res 61 2929 2934 11306470 1:CAS:528:DC%2BD3MXivFGqsro%3D
24. E Buchdunger J Zimmermann H Mett T Meyer M Müller BJ Druker, et al. 1996 Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative Cancer Res 56 100 104 8548747 1:CAS:528:DyaK28Xit1Chsg%3D%3D
25. C Oetzel T Jonuleit A Gotz H van der Kuip H Michels J Duyster, et al. 2000 The tyrosine kinase inhibitor CGP 57148 (STI-571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X Clin Cancer Res 6 1958 1968 10815921 1:CAS:528:DC%2BD3cXktVWisbo%3D
26. AD Van den Abbeele RD Badawi 2002 Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs) Eur J Cancer 38 suppl 5 S60 S65 12528774
27. CH Holdsworth RD Badawi JB Manola MF Kijewski DA Israel GD Demetri, et al. 2007 CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor Am J Roentgenol 189 W324 W330 10.2214/AJR.07.2496 (Pubitemid 350174810)
28. R Bechtold M Chen TA Stanton PD Savage EA Levine 2003 Cystic changes in hepatic and peritoneal metastases from gastrointestinal stromal tumors treated with Gleevec Abdom Imaging 28 808 814 14753595 10.1007/s00261-003-0021-2 1:STN:280:DC%2BD2c%2Flt1Kisg%3D%3D
29. JY Blay A Le Cesne I Ray-Coquard B Bui F Duffaud C Delbaldo, et al. 2007 Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group J Clin Oncol 25 1107 1113 17369574 10.1200/JCO.2006.09.0183 1:CAS:528:DC%2BD2sXksVyrs7s%3D (Pubitemid 46596763)
30. H Choi C Charnsangavej SC Faria EP Tamm RS Benjamin MM Johnson, et al. 2004 CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG-PET findings Am J Roentgenol 183 1619 1628
31. H Choi C Charnsangavej SC Faria HA Macapinlac MA Burgess SR Patel, et al. 2007 Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria J Clin Oncol 25 1753 1759 17470865 10.1200/JCO.2006.07.3049 (Pubitemid 46797957)